Apimex 100mg or 500mg Injection
Clinical Summary
Quick overview from the medicine insert
Indication
Pemetrexed is indicated for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.
Dosage (summary)
The recommended dose of Pemetrexed for NSCLC is 500 mg/m² administered as an intravenous infusion over 30 minutes on the first day of each 21-day treatment cycle. For malignant pleural mesothelioma, the same dosage regimen is followed.
Onset of Action / Duration
The onset of action is typically observed within a few days, with maximum effect seen after several weeks of treatment.
Special Populations
- Elderly patients
- Patients with renal impairment
- Patients with hepatic impairment
Pregnancy & Breastfeeding
Pemetrexed is contraindicated in pregnancy and lactation due to potential harm to the fetus and nursing infant. Effective contraception should be used during treatment.
Key Drug Interactions
- Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of toxicity.
- Caution is advised when used with other myelosuppressive agents.
Contraindications
- Hypersensitivity to pemetrexed or any of its components
- Severe renal impairment (creatinine clearance < 45 mL/min)
- Pregnancy and lactation
Common side effects
- Nausea and vomiting
- Fatigue
- Anemia
- Neutropenia
- Thrombocytopenia
- Rash
Counselling Points
- Patients should be advised to report any signs of infection, unusual bruising or bleeding, or severe gastrointestinal symptoms.
- Ensure adequate hydration before and after administration.
- Discuss the importance of regular blood tests to monitor blood counts.
Serious warnings
- Pemetrexed can cause severe myelosuppression; monitor blood counts regularly.
- Use caution in patients with renal impairment; dose adjustment may be necessary.
- Patients should be monitored for signs of pulmonary toxicity.
Important Disclaimer
The Apimex 100mg or 500mg Injection professional information leaflet below is the property of Astral Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
